Literature DB >> 15509623

The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations.

Tetsutaro Ozawa1, Dominic Paviour, Niall P Quinn, Keith A Josephs, Hardev Sangha, Linda Kilford, Daniel G Healy, Nick W Wood, Andrew J Lees, Janice L Holton, Tamas Revesz.   

Abstract

Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes. To investigate the spectrum of clinicopathological correlations, we performed a semi-quantitative pathological analysis of 100 MSA cases with well-characterized clinical phenotypes. In 24 areas, chosen from both the striatonigral (StrN) and olivopontocerebellar (OPC) regions, the severity of neuronal cell loss and gliosis as well as the frequency of glial (oligodendroglial) cytoplasmic inclusions (GCIs) and neuronal cytoplasmic inclusions (NCIs) were determined. Clinical information was abstracted from the patients' medical records, and the severity of bradykinesia in the first year of disease onset and in the final stages of disease was graded retrospectively. The degree of levodopa responsiveness and the presence or absence of cerebellar ataxia and autonomic symptoms were also recorded. We report that 34% of the cases were SND- and 17% were OPCA-predominant, while the remainder (49%) had equivalent SND and OPCA pathology. We found a significant correlation between the frequency of GCIs and the severity of neuronal cell loss, and between these pathological changes and disease duration. Our data also suggest that GCIs may have more influence on the OPC than on the StrN pathology. Moreover, we raise the possibility that a rapid process of neuronal cell loss, which is independent of the accumulation of GCIs, occurs in the StrN region in MSA. There was no difference in the frequency of NCIs in the putamen, pontine nucleus and inferior olivary nucleus between the SND and OPCA subtypes of MSA, confirming that this pathological abnormality is not associated with a particular subtype of the disease. In the current large post-mortem series, 10% of the cases had associated Lewy body pathology, suggesting that this is not a primary process in MSA. As might be expected, there was a significant difference in the severity of bradykinesia and the presence of cerebellar signs between the pathological phenotypes: the SND phenotype demonstrates the most severe bradykinesia and the OPCA phenotype the more frequent occurrence of cerebellar signs, confirming that the clinical phenotype is dependent on the distribution of pathology within the basal ganglia and cerebellum. Putaminal involvement correlated with a poor levodopa response in MSA. Our finding that relatively mild involvement of the substantia nigra is associated clinically with manifest parkinsonism, while more advanced cerebellar pathology is required for ataxia, may explain why the parkinsonian presentation is predominant over ataxia in MSA.

Entities:  

Mesh:

Year:  2004        PMID: 15509623     DOI: 10.1093/brain/awh303

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  137 in total

1.  Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C).

Authors:  Esteban Muñoz; Alex Iranzo; Sebastian Rauek; Francisco Lomeña; Judith Gallego; Doménec Ros; Joan Santamaría; Eduardo Tolosa
Journal:  J Neurol       Date:  2011-06-03       Impact factor: 4.849

2.  Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.

Authors:  Keita Kuya; Yuki Shinohara; Fuminori Miyoshi; Shinya Fujii; Yoshio Tanabe; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2016-01-16       Impact factor: 2.804

3.  Globular glial tauopathies (GGT): consensus recommendations.

Authors:  Zeshan Ahmed; Gabor G Kovacs; Eileen H Bigio; Herbert Budka; Dennis W Dickson; Isidro Ferrer; Bernardino Ghetti; Giorgio Giaccone; Kimmo J Hatanpaa; Janice L Holton; Keith A Josephs; James Powers; Salvatore Spina; Hitoshi Takahashi; Charles L White; Tamas Revesz
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

Review 4.  Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy.

Authors:  B Segarane; A Li; R Paudel; S Scholz; J Neumann; A Lees; T Revesz; J Hardy; C J Mathias; N W Wood; J Holton; H Houlden
Journal:  Neurology       Date:  2009-03-31       Impact factor: 9.910

5.  Significance of the hot-cross bun sign on T2*-weighted MRI for the diagnosis of multiple system atrophy.

Authors:  Kazushi Deguchi; Kazuyo Ikeda; Kodai Kume; Tadayuki Takata; Yohei Kokudo; Masaki Kamada; Tetsuo Touge; Naomi Honjo; Tsutomu Masaki
Journal:  J Neurol       Date:  2015-04-07       Impact factor: 4.849

6.  Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

Authors:  Junchao Tong; Lee-Cyn Ang; Belinda Williams; Yoshiaki Furukawa; Paul Fitzmaurice; Mark Guttman; Isabelle Boileau; Oleh Hornykiewicz; Stephen J Kish
Journal:  Neurobiol Dis       Date:  2015-06-21       Impact factor: 5.996

7.  Putative neuropathological interactions in MSA: focus in the rostral ventrolateral medulla.

Authors:  E E Benarroch; A M Schmeichel; J E Parisi; P A Low
Journal:  Clin Auton Res       Date:  2015-03-05       Impact factor: 4.435

8.  Different loss of dopamine transporter according to subtype of multiple system atrophy.

Authors:  Hae Won Kim; Jae Seung Kim; Minyoung Oh; Jungsu S Oh; Sang Joo Lee; Seung Jun Oh; Sun Ju Chung; Chong Sik Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-19       Impact factor: 9.236

9.  Bladder dysfunction in a transgenic mouse model of multiple system atrophy.

Authors:  Mathieu Boudes; Pieter Uvin; Silvia Pinto; Thomas Voets; Clare J Fowler; Gregor K Wenning; Dirk De Ridder; Nadia Stefanova
Journal:  Mov Disord       Date:  2013-02-20       Impact factor: 10.338

Review 10.  Parkinson's disease and parkinsonism: neuropathology.

Authors:  Dennis W Dickson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.